Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of rilzabrutinib versus placebo in adults with active IgG4-related disease
CTR20254298Phase 3Active
- Sponsor
- Sanofi
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rilzabrutinib in IgG4-related disease (IgG4-RD), sponsored by Sanofi. Started Dec 2025; status: active.
02
Drugs
rilzabrutinib
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on CTR20254298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254298.